Treatment with danazol and plasma glucagon concentration.

Gareth Williams, F. Lofts, HS Fuessl, S Bloom
In: BMJ · 1985 · vol. 291(6503) , pp. 1155–1156 · doi:10.1136/bmj.291.6503.1155 · PMID:3931833 · PMC1417875 · W1969498424
article OA: bronze CC0 ⤵ 5 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-08 ⓘ

This study found that danazol treatment is associated with severe hyperglucagonaemia, with some patients showing levels suggestive of glucagonoma, necessitating awareness to avoid unnecessary investigations.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The association between treatment with danazol and hyperglucagonaemia was studied. Plasma glucagon concentrations were measured during an oral glucose tolerance test in seven women taking danazol and six healthy controls not taking danazol. Results showed that treatment with danazol is associated with severe hyperglucagonaemia, and in three patients glucagon concentrations reached the range suggestive of glucagonoma. It is important to recognise that this increasingly used drug may cause severe hyperglucagonaemia to prevent patients treated with danazol undergoing unnecessary investigations to localise glucagonoma.

My notes (saved in your browser only)

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (6)

Cited by (5)

Source provenance

europepmc
last seen: 2026-06-30T06:11:02.404677+00:00
openalex
last seen: 2026-05-11T05:08:23.114259+00:00
License: CC0 · commercial use OK